All Oncology News

Michael E. Williams, MD, discusses emerging regimens on the horizon in mantle cell lymphoma, the potential of BCL-2 inhibition, and whether chemotherapy can be removed entirely from the treatment landscape.

Clovis has stopped clinical development of rociletinib, its once promising EGFR inhibitor for the treatment of patients with EGFR T790M–mutated non–small cell lung cancer.

Kenneth Anderson, MD, PhD, discusses the role of APRIL/BCMA and what potential the targeted agent BION-1301 may have in blocking multiple myeloma cell proliferation, as well as reducing drug resistance and immunosuppression in the tumor microenvironment.

The European Commission has approved eribulin mesylate (Halaven) as a treatment for patients with advanced or unresectable liposarcoma following anthracycline-based chemotherapy.

Regorafenib (Stivarga) improved overall survival versus best supportive care in patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

The FDA has granted the PDGFRα antagonist olaratumab a priority review for use in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.

The FDA has granted a priority review to an application to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Abiraterone acetate, alone or in combination with low-dose steroids, has been intensely investigated in recent years for the treatment of progressive CRPC in patients who have received prior chemotherapy or who were treatment-naïve.

Global collaboration applies Wistar expertise to promising Cormorant therapeutic drug development.

Robert Pili, MD, discusses the results and significance of an early-phase trial looking at the combination of entinostat and interleuken-2 and how it could shake up the treatment paradigm for renal cell carcinoma.

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Chris Barker, MD, discusses a study investigating radiation therapy plus the hedgehog pathway inhibitor vismodegib (Erivedge) in patients with locally advanced basal cell carcinoma of the head and neck.

In an ongoing randomized phase III trial, researchers are looking at lenalidomide (Revlimid) compared with observation in patients with asymptomatic high-risk smoldering multiple myeloma.

Bone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Patrick Ott, MD, PhD, discusses toxicity management and patient selection considerations required with the combination of nivolumab (Opdivo)/ipilimumab (Yervoy), and its role in BRAF-mutant melanoma.

The Committee for Medicinal Products for Human Use has recommended the first-line approval of bevacizumab (Avastin) in combination with erlotinib (Tarceva) for patients with advanced or metastatic EGFR-mutant non–small cell lung cancer.

Obinutuzumab (Gazyva) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use for use in combination with bendamustine as a treatment for patients with follicular lymphoma who previously received chemotherapy.

The Committee for Medicinal Products for Human Use has recommended the frontline approval for ibrutinib (Imbruvica) as a single-agent for patients with chronic lymphocytic leukemia.

Everolimus (Afinitor) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use as a treatment for patients with progressive, unresectable or metastatic, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors.

Charles M. Perou, PhD, discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome, and how determining intrinsic subtypes can help guide breast cancer therapy.

Adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression or death by 26% compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

Omid Hamid, MD, outlines a selection of combinations that are on the horizon in advanced melanoma.

Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.

Navesh K. Sharma, DO, PhD, discusses findings on a study looking at the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in liver metastatic colorectal cancer.

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.

The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment. This is the main finding of a study led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center.

Melanoma, mesothelioma are the focus of first joint studies.

The research will test how 8-chloro-adenosine functions in patients with refractory/relapsed AML.

New findings could lead to anti-cancer drug developments that reverse immunosuppressive environments.

Sara Hurvitz, MD, discusses ongoing neoadjuvant studies in HER2-positive breast cancer, as well as what the future holds for neoadjuvant therapy.